{"name":"Lokien van Nunen","slug":"lokien-van-nunen","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Regadenoson central - peripheral","genericName":"Regadenoson central - peripheral","slug":"regadenoson-central-peripheral","indication":"Nuclear stress test for coronary artery disease","status":"phase_3"},{"name":"Regadenoson central -central","genericName":"Regadenoson central -central","slug":"regadenoson-central-central","indication":"Nuclear stress test for coronary artery disease","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Regadenoson peripheral - central","genericName":"Regadenoson peripheral - central","slug":"regadenoson-peripheral-central","indication":"Pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise","status":"phase_3"},{"name":"Regadenoson peripheral - peripheral","genericName":"Regadenoson peripheral - peripheral","slug":"regadenoson-peripheral-peripheral","indication":"Pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise","status":"phase_3"}]}],"pipeline":[{"name":"Regadenoson central - peripheral","genericName":"Regadenoson central - peripheral","slug":"regadenoson-central-peripheral","phase":"phase_3","mechanism":"Regadenoson central - peripheral acts as an adenosine A2A receptor agonist.","indications":["Nuclear stress test for coronary artery disease"],"catalyst":""},{"name":"Regadenoson peripheral - central","genericName":"Regadenoson peripheral - central","slug":"regadenoson-peripheral-central","phase":"phase_3","mechanism":"Regadenoson is an adenosine A2A receptor agonist that causes coronary vasodilation to increase blood flow, used for cardiac stress testing.","indications":["Pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise"],"catalyst":""},{"name":"Regadenoson peripheral - peripheral","genericName":"Regadenoson peripheral - peripheral","slug":"regadenoson-peripheral-peripheral","phase":"phase_3","mechanism":"Regadenoson is an adenosine A2A receptor agonist that causes peripheral vasodilation to increase blood flow, used as a pharmacologic stress agent for cardiac imaging.","indications":["Pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise","Peripheral vascular insufficiency and claudication (investigational)"],"catalyst":""},{"name":"Regadenoson central -central","genericName":"Regadenoson central -central","slug":"regadenoson-central-central","phase":"phase_3","mechanism":"Regadenoson central acts as an adenosine A2A receptor agonist, increasing coronary blood flow.","indications":["Nuclear stress test for coronary artery disease"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}